The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders

Translational Psychiatry

Volumn 4, Issue 11, 2014, Pages

  Pagan, C ^a,b,c,d,j   Delorme, R ^b,c,d,e   Callebert, J ^a,b   Goubran Botros, H ^c   Amsellem, F ^d,e   Drouot, X ^d,f,k   Boudebesse, C ^d,f,g   Dudal, K L ^d,g   Ngo Nguyen, N ^d   Laouamri, H ^d   Gillberg, C ^h,i   Leboyer, M ^d,f,g   Bourgeron, T ^b,c,d   Launay, J M ^a,b,d  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d FONDATION FONDAMENTAL   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f INSERM   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j HOSPICES CIVILS DE LYON   (France)

^k POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; N ACETYLSEROTONIN; SEROTONIN; BIOLOGICAL MARKER; N-ACETYLSEROTONIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; AUTISM; BIOCHEMISTRY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FATHER; FEMALE; FIRST DEGREE RELATIVE; HORMONE BLOOD LEVEL; HUMAN; HYPERSEROTONEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELATONIN BLOOD LEVEL; MOTHER; N ACETYLSEROTONIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEROTONIN BLOOD LEVEL; SIBLING; SIGNAL TRANSDUCTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CHILD; GENETICS; PARENT; PHYSIOLOGY;

ADOLESCENT; ADULT; BIOMARKERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; HUMANS; MALE; MELATONIN; PARENTS; SEROTONIN; SIBLINGS; SIGNAL TRANSDUCTION;

EID: 84919598829     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.120     Document Type: Article

References (72)

1. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2013; 383: 896-910.
2. Huguet G, Ey E, Bourgeron T. The genetic landscapes of autism spectrum disorders. Annu Rev Genom Hum Genet 2013; 14: 191-213.
3. Ecker C, Marquand A, Mourao-Miranda J, Johnston P, Daly EM, Brammer MJ et al. Describing the brain in autism in five dimensions-magnetic resonance imagingassisted diagnosis of autism spectrum disorder using a multiparameter classification approach. J Neurosci 2010; 30: 10612-10623.
4. Koldewyn K, Yendiki A, Weigelt S, Gweon H, Julian J, Richardson H et al. Differences in the right inferior longitudinal fasciculus but not general disruption of white matter tracts in children with autism spectrum disorders. Proc Natl Acad Sci USA 2014; 111: 1981-1986.
5. Elsabbagh M, Mercure E, Hudry K, Chandler S, Pasco G, Charman T et al. Infant neural sensitivity to dynamic eye gaze is associated with later emerging autism. Curr Biol 2012; 22: 338-342.
6. Jones W, Klin A. Attention to eyes is present but in decline in 2-6-month-old infants later diagnosed with autism. Nature 2013; 504: 427-431.
7. Delorme R, Ey E, Toro R, Leboyer M, Gillberg C, Bourgeron T et al. Progress toward treatments for synaptic defects in autism. Nat Med 2013; 19: 685-694.
8. Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006; 27: 254-289.
9. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012; 17: 389-401.
10. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology 2014; 231: 1201-1216.
11. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961; 58: 315-320.
12. Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014; 24: 919-929.
13. Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry 1999; 45: 158-163.
14. Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y et al. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995; 25: 641-654.
15. Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P et al. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett 2000; 21: 31-34.
16. Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry 2005; 57: 134-138.
17. Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsater H et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008; 13: 90-98.
18. Tordjman S, Anderson GM, Bellissant E, Botbol M, Charbuy H, Camus F et al. Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder. Psychoneuroendocrinology 2012; 37: 1990-1997.
19. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
20. Bourgeron T. The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb Symp Quant Biol 2007; 72: 645-654.
21. Lewy AJ, Cutler NL, Sack RL. The endogenous melatonin profile as a marker for circadian phase position. J Biol Rhythms 1999; 14: 227-236.
22. Lewy AJ, Bauer VK, Hasler BP, Kendall AR, Pires ML, Sack RL et al. Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin. Brain Res 2001; 918: 96-100.
23. Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011; 41: 175-184.
24. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23: 482-485.
25. Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 2012; 42: 1729-1737, author reply 1738.
26. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlledrelease melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36: 741-752.
27. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebocontrolled trial. J Sleep Res 2012; 21: 700-709.
28. Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbances in children with Asperger disorder. J Child Adolesc Psychopharmacol 2003; 13: 83-95.
29. Jang SW, Liu X, Pradoldej S, Tosini G, Chang Q, Iuvone PM et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci USA 2010; 107: 3876-3881.
30. Sompol P, Liu X, Baba K, Paul KN, Tosini G, Iuvone PM et al. N-acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep-deprived mice. Proc Natl Acad Sci USA 2011; 108: 8844-8849.
31. Constantino JN, Przybeck T, Friesen D, Todd RD. Reciprocal social behavior in children with and without pervasive developmental disorders. J Dev Behav Pediatr 2000; 21: 2-11.
32. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24: 659-685.
33. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000; 30: 205-223.
34. Lam KS, Aman MG. The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord 2007; 37: 855-866.
35. Kema IP, Schellings AM, Hoppenbrouwers CJ, Rutgers HM, de Vries EG, Muskiet FA et al. High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta 1993; 221: 143-158.
36. Brownstein M, Saavedra JM, Axelrod J. Control of pineal N-acetylserotonin by a beta adrenergic receptor. Mol Pharmacol 1973; 9: 605-611.
37. Kenney K, Brechtel C, Takahashi H, Kurohara K, Anderson P, Gibbs CJ Jr et al. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann Neurol 2000; 48: 395-398.
38. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
39. Ritvo E, Yuwiler A, Geller E, Plotkin S, Mason A, Saeger K et al. Maturational changes in blood serotonin levels and platelet counts. Biochem Med 1971; 5: 90-96.
40. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003; 55: 325-395.
41. Courchesne E, Campbell K, Solso S. Brain growth across the life span in autism: age-specific changes in anatomical pathology. Brain Res 2011; 1380: 138-145.
42. Chaste P, Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK et al. Adjusting head circumference for covariates in autism: clinical correlates of a highly heritable continuous trait. Biol Psychiatry 2013; 74: 576-584.
43. Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep 2000; 23: 1043-1051.
44. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
45. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningnesseveningness in human circadian rhythms. Int J Chronobiol 1976; 4: 97-110.
46. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
47. Maronde E, Saade A, Ackermann K, Goubran-Botros H, Pagan C, Bux R et al. Dynamics in enzymatic protein complexes offer a novel principle for the regulation of melatonin synthesis in the human pineal gland. J Pineal Res 2011; 51: 145-155.
48. Obsil T, Ghirlando R, Klein DC, Ganguly S, Dyda F. Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase complex. a role for scaffolding in enzyme regulation. Cell 2001; 105: 257-267.
49. McBride PA, Anderson GM, Hertzig ME, Snow ME, Thompson SM, Khait VD et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1998; 37: 767-776.
50. Kuperman S, Beeghly JH, Burns TL, Tsai LY. Serotonin relationships of autistic probands and their first-degree relatives. J Am Acad Child Psychiatry 1985; 24: 186-190.
51. Leventhal BL, Cook EH Jr, Morford M, Ravitz A, Freedman DX. Relationships of whole blood serotonin and plasma norepinephrine within families. J Autism Dev Disord 1990; 20: 499-511.
52. Cook EH Jr., Leventhal BL, Heller W, Metz J, Wainwright M, Freedman DX et al. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiat Clin Neurosci 1990; 2: 268-274.
53. Abney M, McPeek MS, Ober C. Broad and narrow heritabilities of quantitative traits in a founder population. Am J Hum Genet 2001; 68: 1302-1307.
54. Hallam KT, Olver JS, Chambers V, Begg DP, Mc Grath C, Norman TR et al. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006; 31: 867-875.
55. Coté F, Fligny C, Bayard E, Launay JM, Gershon MD, Mallet J et al. Maternal serotonin is crucial for murine embryonic development. Proc Natl Acad Sci USA 2007; 104: 329-334.
56. Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC et al. A transient placental source of serotonin for the fetal forebrain. Nature 2011; 472: 347-350.
57. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S et al. Oxytocinmediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 2014; 343: 675-679.
58. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 2010; 107: 4389-4394.
59. Mottolese R, Redouté J, Costes N, Le Bars D, Sirigu A. Switching brain serotonin with oxytocin. Proc Natl Acad Sci USA 2014; 111: 8637-8642.
60. Hammock E, Veenstra-van der Weele J, Yan Z, Kerr TM, Morris M, Anderson GM et al. Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. J Am Acad Child Adolesc Psychiatry 2012; 51: 712-721.
61. Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, and possible biopsychosocial aetiologies. Sleep Med Rev 2009; 13: 403-411.
62. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum disorder. Sleep Med 2010; 11: 659-664.
63. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011; 53: 783-792.
64. Wirz-Justice A, Schellings MJ, Feer H. Diurnal and seasonal variations in human platelet serotonin in man. J Neural Transm 1977; 41: 7-15.
65. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin indiabetes. Thromb Res 1994; 75: 569-576.
66. Psarakis S, Brown GM, Grota LJ. Analgesia induced by N-acetylserotonin in the central nervous system. Life Sci 1988; 42: 1109-1116.
67. Klemm P, Hecker M, Stockhausen H, Wu CC, Thiemermann C. Inhibition by N-acetyl-5-hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. Br J Pharmacol 1995; 115: 1175-1181.
68. Pagan C Delorme R Launay J-M Bourgeron T. Alterations of the serotonin-melatonin pathway in autism spectrum disorders: biological evidence and clinical consequences. In: Powell, CM, Monteggia, LM (eds). The Autisms-Molecules to Model Systems. Oxford University Press: New York, NY, USA, 2013, 240-273.
69. Toma C, Rossi M, Sousa I, Blasi F, Bacchelli E, Alen R et al. Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populations. Mol Psychiatry 2007; 12: 977-979.
70. Etain B, Dumaine A, Bellivier F, Pagan C, Francelle L, Goubran-Botros H et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet 2012; 21: 4030-4037.
71. Galecki P, Szemraj J, Bartosz G, Bienkiewicz M, Galecka E, Florkowski A et al. Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res 2010; 48: 311-317.
72. Kripke DF, Nievergelt CM, Tranah GJ, Murray SS, McCarthy MJ, Rex KM et al. Polymorphisms in melatonin synthesis pathways: possible influences on depression. J Circadian Rhythms 2011; 9: 8.